ABSTRACT The smoking habits of 202 patients presenting with sarcoidosis, as recorded in the clinical case records, were compared with figures from the General Household Surveys (GHS) to determine whether there was any association between smoking habit and sarcoidosis. In 19 there was no record of smoking habit. Of the remaining 183 patients, 40 (21 9%) were smokers, which was significantly less than expected from the GHS figures (p < 0 001). This association between nonsmoking and sarcoidosis persisted despite further analysis by sex and age distribution and socioeconomic grouping. Statistical likelihood models showed that ex-smokers were similar to current smokers with respect to the association between smoking and sarcoidosis. This association was greatest in those patients with stage I sarcoidosis and less for those with other stages of the disease.
Cigarette smoking has been implicated in the pathogenesis of many respiratory disorders, including bronchial carcinoma and chronic airflow obstruction. In contrast, non-smoking is associated with extrinsic allergic alveolitis' and ulcerative colitis,2 disorders which may have an immunological basis. We discovered that of 11 patients with sarcoidosis only one smoked and we therefore carried out a survey to see if smoking habit was associated in any way with sarcoidosis.
Methods
We reviewed the case notes of patients presenting with sarcoidosis to the Northern General Hospital, Edinburgh; Victoria Hospital, Kirkcaldy; Milesmark Hospital, Dunfermline; Bangour General Hospital, West Lothian; and Peel Hospital, Galashiels; from 1971 to 1982. All patients were seen by consultant physicians with an interest in respiratory medicine and all had either bilateral hilar lymphadenopathy and erythema nodosum or a positive Kveim test reaction or typical histological appearances on biopsy. Staging of sarcoidosis was obtained from the reports of chest radiographs and cross checked with consultants' letters. Details of smoking habit at the time of presentation were usually found in the referral or consultant's letter, and wherever possible was cross checked by reviewing the pulmonary function laboratory records and nursing Kardex notes. For the purpose of this study, patients who were reported to smoke "occasionally" or who smoked a pipe or cigars were classified as being smokers. Ex-smokers were defined as those who were recorded as having stopped smoking at least six months before presentation.
Smoking habits at diagnosis were compared with information obtained from the General Household Surveys (GHS) for 1972-82.3 These give the proportion in four smoking categories (never smoked, exsmoker, light smoker, and heavy smoker) within 12 age/sex groups at two yearly intervals. Thus for each patient in the study an estimate of the proportion of smokers among age and sex matched controls at the time of diagnosis could be obtained. These figures were the basis for determining the "expected" numbers of smokers in our sample of patients with sarcoidosis and the variance of the number of smokers was calculated by summing the individual variances obtained from the binomial distribution. As well as significance tests based on a comparison of the observed and expected numbers of smokers, likelihood models were used to estimate the relative risk of sarcoidosis in smokers and non-smokers and to determine the effect of variables on these risks. These models were extended to consider the relative risks within the four subcategories of smoking habit. In the 787 Douglas, Middleton, Gaddie, Petrie, Choo-Kang, Prescott, Crompton application of the likelihood models likelihood ratio (LR) tests were used to determine the statistical significance of terms in the model (appendix).
Results
We reviewed the case notes of 202 patients with sarcoidosis. In 19 there was no record of smoking habit and these patients were excluded from the analysis. Of the remaining 183 (18-6%) stage III sarcoidosis and in neither of these groups was there a significant difference between the number of smokers observed and that anticipated from the GHS figures, though when the stages were combined there were fewer smokers than expected (p = 0-03). Sixty seven (36-6%) patients had been reported to have erythema nodosum around the time of presentation, 52 of these having stage I disease. Five of these patients with erythema nodosum were smokers, compared with an expected number of 28-9.
Of the variables considered, only the stage of sarcoidosis and the presence or absence of erythema nodosum appeared to exert any influence on the magnitude of the association with non-smoking. Likelihood models were applied to test whether the apparent differences in the relative risks in the various subgroups were significant. Both stage (stage I v other stages) and erythema nodosum (present or absent) considered in isolation were shown to have a significant effect on the magnitude of the relative risk from smoking (LR tests-stage: x2 = 8-9, p = 0-003; erythema nodosum: x2 = 14-7, p < 0-001). When both variables were allowed simultaneously into a multiplicative model, the effect of erythema nodosum was still statistically significant at the 1% level but the statistical significance of stage was lost. The use of a more detailed model incorporating the four smoking categories gave a rather different picture. With a different relative risk of sarcoidosis allowed for within each smoking category, both stage (LR test: X = 16-9, p < 0-0001) and erythema nodosum (LR test: x2 = 8-3, p = 0-004) were again shown to modify these risks. This time, however, when the effect of both variables was considered simultaneously; (table 3) , though the difference between them was not significant (LR test: x2 = 2-5, p = 0-28).
The paradox in the above analysis arises from the contribution of the ex-smokers and in particular the anomalous results in a small group of patients with erythema nodosum and more advanced stages of sarcoidosis. This group has five ex-smokers, compared with an expected number of 2-1, and their effect is critical. In the first analysis presented, where exsmokers and non-smokers were grouped together, the association between smoking and a lower incidence of sarcoidosis was stronger in patients with erythema nodosum, with differences between stage I and other stages possibly incidental (p = 0-11). With exsmokers either considered separately, as in the second analysis, or grouped with smokers, the association appeared to be affected only by whether or not the patient had stage I disease. Comparison of the likelihood according to the alternative models showed a much better fit when ex-smokers were considered separately or included with smokers than when only current smoking was considered. The most simple model that describes the data adequately suggests that regular smoking at any time is associated with a lower incidence of sarcoidosis. Furthermore, this association is stronger in stage I disease, where the estimated relative risk compared with non-smokers is 0-15 (95% confidence limits 0-09-0-24) than in other stages, where the relative risk is 0-59 (0-39-0-89).
Discussion
In this survey smoking was uncommon in patients with sarcoidosis. This was because a high proportion of patients had never smoked and also because there were fewer ex-smokers than expected. It could be argued that the recording of smoking habit in patients referred to hospital is different from a survey of the general population and that many of those patients Douglas, Middleton, Gaddie, Petrie, Choo-Kang, Prescott, Crompton recorded as non-smokers in this study were actually ex-smokers. There was, however, a difference in distribution of smoking habit between the different stages of sarcoidosis (table 2), implying that there was no consistent bias against the recording of exsmokers. Although retrospective analysis of clinical case records has many inherent shortcomings, our findings are consistent in different hospitals and throughout the period of study. In 19 patients there was no record of smoking habit, but even if all these patients had been smokers there would still have been significantly fewer patients smoking than would be expected. Sarcoidosis is frequently asymptomatic and intrathoracic disease is often discovered on a chest radiograph performed as a screening procedure. Nonsmoking habit, however, seems unlikely to have influenced referral for radiography in symptomless patients. This association between non-smoking and sarcoidosis persisted despite further analysis of sex and age distribution and socioeconomic grouping, factors known to influence smoking prevalence. We therefore believe that these results show that nonsmoking is more common in patients with sarcoidosis than in the general population.
The association between sarcoidosis and nonsmoking was greatest in patients with stage I and much less for those with the other stages of the disease. A further study would be required to see whether smoking alters the progression of sarcoidosis from stage I to more extensive pulmonary disease. Erythema nodosum also initially appeared to exert an influence on the magnitude of the association but this did not persist after further statistical analysis. A study of patients with erythema nodosum with or without sarcoidosis would be necessary to discover whether non-smoking is also associated with this condition.
The The reasons why non-smoking is associated with sarcoidosis are unknown. Smoking has been shown to hasten the clearance of inhaled particles from the lung6 and, in vitro, alveolar macrophages from smokers are more active than those from non-smokers.7
Hence the lungs of smokers may be able to remove the antigen or other stimulus that might otherwise go on to produce the histological changes of sarcoidosis. Alternatively, cigarette smoke may suppress T lymphocyte function8 and therefore prevent T cell activation, which is thought to precede the formation of a granuloma. These hypotheses, however, do not explain why those who have stopped smoking for at least six months have a reduced risk of developing sarcoidosis. Whatever the mechanism, our survey suggests that non-smoking is commoner in patients with sarcoidosis than in the general population and that further studies are needed to see whether smoking habit has any influence on the progression or severity of this disorder.
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Appendix: Model for estimation of relative risk Let the probability that a non-smoker has sarcoidosis be denoted by )O (which will remain unknown), and let the relative risk in ex-smokers, light smokers and heavy smokers be denoted rE, rL and rH respectively. Then the corresponding probabilities of having sarcoidosis in these three categories will be AorE, )orL, and AorH.
We will let PN, PE, PL, and PH denote the probabilities that an individual is a non-smoker, ex-smoker, light smoker, and heavy smoker. These terms will in fact depend on the age and sex of the subject and the year to which we are referring and will be obtained from the General Household Survey.
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